Knopp Biosciences (United States)

Recent papers from Knopp Biosciences (United States)

1. The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett’s Esophagus: A Case Series From a Gastrointestinal Surgery CenterForegut The Journal of the American Foregut Society · 2026
2. Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasisCell Reports Methods · 2026
3. High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigensBlood Advances · 2025
4. A Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients With Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results From Q-TABClinical and Translational Gastroenterology · 2023
5. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade DysplasiaGastroenterology · 2023
6. A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's EsophagusClinical and Translational Gastroenterology · 2023
7. Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trialJournal of Allergy and Clinical Immunology · 2023
8. Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disordersAllergy · 2022
9. An Objective, Fully Automated Barrett’s Risk Prediction Assay Outperforms Most Pathologists in Risk Stratifying Barrett’s Esophagus With Low Grade DysplasiaEndoscopy · 2022
10. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp sizeThe Laryngoscope · 2018
11. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromesBlood · 2018
12. Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)Journal of Leukocyte Biology · 2018
13. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral SclerosisJAMA Neurology · 2017
14. Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory DiseaseFrontiers in Medicine · 2017
15. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2014
16. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trialsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2013
17. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristicsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2012
18. Safety, Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult SubjectsThe Journal of Clinical Pharmacology · 2010
19. KNS‐760704 [(6R)‐4,5,6,7‐tetrahydro‐N6‐propyl‐2, 6‐benzothiazole‐diamine dihydrochloride monohydrate] for the Treatment of Amyotrophic Lateral SclerosisCNS Neuroscience & Therapeutics · 2008
20. The therapeutic potential of neuronal KV7 (KCNQ) channel modulators: an updateExpert Opinion on Therapeutic Targets · 2008